This site is intended only for healthcare professionals resident in India
Clinical studies – RA1
The tofacitinib clinical development programme included 2 dose-ranging trials and 5 confirmatory trials. Although other doses have been studied, the recommended dose of tofacitinib is 5 mg BID.
Percentage of ACR20 Responders by Visit for Study IV
Non-responder imputation was used. Patients who withdrew from the study were counted as failures, as were patients who failed to have at least a 20% improvement in joint counts at Month 3.
Adapted from Xeljanz. Local product document. 2022.
Dosing & Administration
Helps protect against RA, PsA and UC
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022